Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective decreased by Canaccord Genuity from $353.00 to $320.00 in a research report sent to investors on Wednesday morning, AnalystRatings.com reports. Canaccord Genuity currently has a hold rating on the biopharmaceutical company’s stock.
A number of other equities analysts have also weighed in on REGN. BidaskClub lowered Regeneron Pharmaceuticals from a sell rating to a strong sell rating in a research report on Wednesday, August 28th. Credit Suisse Group decreased their price target on Regeneron Pharmaceuticals from $333.00 to $325.00 and set a neutral rating for the company in a research report on Wednesday, August 7th. Leerink Swann set a $453.00 price target on Regeneron Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, June 11th. BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals to $344.00 and set a market perform rating for the company in a research report on Wednesday, August 7th. Finally, Cowen reiterated a hold rating and issued a $353.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, July 29th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $394.81.
REGN stock traded up $6.53 during trading hours on Wednesday, hitting $297.36. 25,293 shares of the stock traded hands, compared to its average volume of 677,413. The stock has a 50-day simple moving average of $285.87 and a 200 day simple moving average of $316.55. Regeneron Pharmaceuticals has a one year low of $271.37 and a one year high of $442.00. The company has a market cap of $31.17 billion, a P/E ratio of 14.98, a P/E/G ratio of 1.30 and a beta of 1.14. The company has a current ratio of 3.88, a quick ratio of 3.11 and a debt-to-equity ratio of 0.07.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.60 by $0.69. Regeneron Pharmaceuticals had a return on equity of 25.79% and a net margin of 28.59%. The business had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same quarter last year, the company posted $5.45 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 20.3% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals will post 19.22 earnings per share for the current year.
In related news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total value of $48,611,959.60. 11.84% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Accurate Investment Solutions Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $31,000. HM Payson & Co. acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $31,000. Thor Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $32,000. Coastal Capital Group Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $38,000. Finally, Focused Wealth Management Inc increased its holdings in shares of Regeneron Pharmaceuticals by 1,333.3% during the 2nd quarter. Focused Wealth Management Inc now owns 129 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 120 shares during the last quarter. 66.54% of the stock is owned by institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Read More: Why are gap-down stocks important?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.